I am a pediatric oncology physician-scientist with an active basic and translational research program focused on cellular and molecular immunology and immuno-oncology. Our research has focused on defining vulnerabilities within Osteosarcoma tumor microenvironment that can be translated into clinical trials in the next few years. We have already opened the Natalizumab trial (NCT03811886) targeting un-resectable pulmonary Osteosarcoma, and we are working on opening several other clinical trials targeting refractory, metastatic and recurrent Osteosarcoma.